Insulet Corporation $PODD Shares Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC increased its position in shares of Insulet Corporation (NASDAQ:PODD) by 262.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,579 shares of the medical instruments supplier’s stock after buying an additional 3,317 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Insulet were worth $887,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in PODD. NewEdge Advisors LLC grew its position in shares of Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 64 shares during the last quarter. Cresset Asset Management LLC raised its position in Insulet by 7.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares during the last quarter. Cerity Partners LLC raised its position in Insulet by 68.7% in the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares during the last quarter. Sei Investments Co. boosted its stake in Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after purchasing an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina grew its position in Insulet by 2.5% during the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after purchasing an additional 791 shares during the last quarter.

Analyst Ratings Changes

PODD has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their target price on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada lowered their price target on Insulet from $280.00 to $245.00 and set an “outperform” rating on the stock in a report on Monday. Bank of America dropped their price target on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. UBS Group set a $219.00 price objective on Insulet in a research note on Thursday, June 11th. Finally, Sanford C. Bernstein decreased their price objective on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average price target of $235.25.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.36% of the stock is currently owned by insiders.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Multiple law firms issued reminders and investor alerts about a securities class action against Insulet, with lead-plaintiff deadlines set for August 31, 2026. These notices generally keep the stock in the spotlight but do not by themselves change the underlying case. Article link
• Neutral Sentiment: Another law firm announced that a class action lawsuit has been filed against Insulet and certain officers on behalf of investors who bought shares during the alleged class period, reinforcing concerns about legal overhang for the company. Article link
• Neutral Sentiment: Prior reporting cited allegations that two Omnipod corrections may have exposed broader quality-control issues and contributed to a sharp earlier selloff, which helps explain why litigation-related headlines remain a focus for traders. Article link

Insulet Stock Up 3.2%

Shares of Insulet stock opened at $164.43 on Friday. The company has a market cap of $11.39 billion, a P/E ratio of 38.24, a PEG ratio of 1.11 and a beta of 1.11. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a one year low of $138.79 and a one year high of $354.88. The firm has a fifty day moving average of $152.81 and a two-hundred day moving average of $207.20.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the firm earned $1.02 earnings per share. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts forecast that Insulet Corporation will post 6.45 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.